TX-MOGAS-INDUSTRIES
MOGAS Industries, Inc. (MOGAS) will be celebrating its 50-year anniversary with a commemorative celebration on Thursday, May 18th, 2023. The company officially began at 8:20 p.m. on May 17th, 1973.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005845/en/
Matt Mogas (left) and Louis Mogas (right) pose next to a large MOGAS ball valve (Photo: Business Wire)
MOGAS has earned a global reputation as a leading severe service manufacturer for the most extreme industrial applications in power, mining, refining, petrochemical/chemical, oil & gas, and specialty application industries. Significant business units include Severe Service Valves, Systems & Consulting (modules), Surface Technologies (coatings), Service & Reliability.
Louis Mogas formed Mogas Machine Works in 1973 with 16 employees working under 19,000 sq ft of manufacturing space on a couple of acres. Today, privately owned MOGAS Industries employs over 325 people across six countries. Their Houston-based headquarters now has 100,000 sq ft of manufacturing capacity spanning 15 acres. Campus improvements, such as 'Class A' corporate offices, an advanced coating facility, a 3-acre wooded park and numerous facility upgrades attest to MOGAS' success—not only as a significant manufacturer—but also to the Company staying true to its original business philosophy of putting people before profits.
A significant part of MOGAS sales is international, with sales and service centers in China, Australia, Canada, South America, Africa, The Middle East, Europe and India. With representatives and technicians in more than 40 countries, MOGAS is known for partnering with its customers to meet the ever-increasing challenges of severe-service applications.
On the occasion of the company’s 50th anniversary, MOGAS CEO/COO Matt Mogas notes: “I feel incredibly blessed to have worked with so many great employees, representatives, and customers these last 33 years. They have made a meaningful impact on MOGAS Industries and me personally. I feel honored to stand on the shoulders of the great men that came before me at MOGAS, especially Sam Furman, Tommy Bright, Cary Lorenz and of course my father, Louis Mogas, the grand architect, master, creator of our culture, beliefs and vision.”
Serving the community is ingrained in the MOGAS culture. The Company contributes significant resources to many worthy causes and enthusiastically supports their employees’ robust spirit of volunteerism. Charitable contributions to organizations include: Ronald McDonald House, MS150, Camp for All, The Periwinkle Foundation, and business partnerships with local elementary and junior schools. The Company also supports private initiatives for public good, focusing on quality of life.
The entire MOGAS organization is proud of this momentous achievement.
For more information, please contact MOGAS Industries at 281.449.0291 or Email: marketing@mogas.com
About MOGAS Industries, Inc.
MOGAS Industries Inc. is the most trusted severe service technology company, providing world-renowned services and the best severe service, application-specific products for critical applications in power, mining, oil & gas, refining, chemical/petrochemical and specialty industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005845/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom